Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis

BACKGROUND: The application of vedolizumab (VDZ) subcutaneous (SC) formulation has brought more convenience and hope to patients with moderate-to-severe inflammatory bowel diseases (IBDs) in the coronavirus disease 2019 context. OBJECTIVE: This study aimed to systematically evaluate all previous stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiong, Tang, Xing-zhou, Liu, Fang, Liu, De-wu, Cao, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141260/
https://www.ncbi.nlm.nih.gov/pubmed/37124368
http://dx.doi.org/10.1177/17562848231166227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141260/
https://www.ncbi.nlm.nih.gov/pubmed/37124368
http://dx.doi.org/10.1177/17562848231166227

Ejemplares similares